Skip to main content
. Author manuscript; available in PMC: 2021 Jan 17.
Published in final edited form as: ACS Chem Biol. 2019 Dec 16;15(1):83–92. doi: 10.1021/acschembio.9b00580

Figure 1.

Figure 1.

MAPK activity of MDA-MB-231 cell lysates towards SOX-MEF2A peptide. MDA-MB-231 cells treated with (a) EGF, (b) anisomycin, (c) MEK inhibitor U0126, and (d) JNK inhibitor JNK-IN-8, showing four experimental replicates per treatment.